Taysha Gene Therapies (TSHA) Operating Margin (2022 - 2025)
Historic Operating Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1347.08%.
- Taysha Gene Therapies' Operating Margin rose 5683000.0% to 1347.08% in Q2 2025 from the same period last year, while for Sep 2025 it was 1618.54%, marking a year-over-year decrease of 7332900.0%. This contributed to the annual value of 1097.55% for FY2024, which is 6287200.0% down from last year.
- Per Taysha Gene Therapies' latest filing, its Operating Margin stood at 1347.08% for Q2 2025, which was up 5683000.0% from 930.54% recorded in Q1 2025.
- Taysha Gene Therapies' 5-year Operating Margin high stood at 7388.54% for Q1 2022, and its period low was 1915.38% during Q2 2024.
- Its 4-year average for Operating Margin is 636.8%, with a median of 582.03% in 2023.
- In the last 5 years, Taysha Gene Therapies' Operating Margin tumbled by -77404100bps in 2023 and then skyrocketed by 5683000bps in 2025.
- Taysha Gene Therapies' Operating Margin (Quarter) stood at 4135.33% in 2022, then crashed by -111bps to 450.78% in 2023, then crashed by -119bps to 985.76% in 2024, then tumbled by -37bps to 1347.08% in 2025.
- Its Operating Margin stands at 1347.08% for Q2 2025, versus 930.54% for Q1 2025 and 985.76% for Q4 2024.